{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:59:48Z","timestamp":1780898388397,"version":"3.54.1"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T00:00:00Z","timestamp":1780876800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Public Health"],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Although COVID-19 vaccines are highly effective in preventing infection and severe disease, their cardiovascular safety, particularly regarding arrhythmic risk, continues to raise concerns.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A disproportionality analysis was conducted using the U.S. Vaccine Adverse Event Reporting System (VAERS) to evaluate arrhythmia-related AEs reported between December 2020 and January 2025. Adverse events (AEs) were identified using MedDRA Preferred Terms, and signal strength was assessed by Reporting Odds Ratio (ROR) and Proportional Reporting Ratio (PRR).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 52,518 reports were identified, with a median onset interval of 1 day after vaccination. The most frequent AEs were tachycardia (40.5%) and atrial fibrillation (16.9%). Atrial flutter, extrasystoles, and atrioventricular block exhibited the strongest signals. Severe events primarily involved ventricular and conduction abnormalities, particularly among older adults and male individuals. Reports involving mRNA vaccines were predominantly characterized by tachyarrhythmia-related events, whereas findings for bradyarrhythmia- and conduction-related events after adenoviral vector vaccination should be interpreted cautiously.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cardiac arrhythmias following COVID-19 vaccination typically occurred within the early post-vaccination period and demonstrated clear platform- and population-specific differences. Although the overall risk is low, enhanced early monitoring and stratified pharmacovigilance are warranted to optimize vaccine safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpubh.2026.1762082","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:33:54Z","timestamp":1780896834000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cardiac arrhythmias following COVID-19 vaccination: insights from the U.S. vaccine adverse event reporting system (VAERS), December 2020\u2014January 2025, United States"],"prefix":"10.3389","volume":"14","author":[{"given":"Yi","family":"Lu","sequence":"first","affiliation":[{"name":"Department of Cardiology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Jiang","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangwei","family":"Ding","sequence":"additional","affiliation":[{"name":"Department of Cardiology, The Affiliated Taizhou People's Hospital of Nanjing Medical University, Taizhou School of Clinical Medicine, Nanjing Medical University, Taizhou","place":["Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.15585\/mmwr.mm7005e1","article-title":"Demographic characteristics of persons vaccinated during the first month of the COVID-19 vaccination program - United States, December 14, 2020-January 14, 2021","volume":"70","author":"Painter","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep."},{"key":"B2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/s41541-021-00356-x","article-title":"Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic","volume":"6","author":"Mendon\u00e7a","year":"2021","journal-title":"NPJ Vaccines."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2201","DOI":"10.1001\/jama.2021.5374","article-title":"Reactogenicity following receipt of mRNA-based COVID-19 vaccines","volume":"325","author":"Chapin-Bardales","year":"2021","journal-title":"JAMA."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1463","DOI":"10.3390\/vaccines9121463","article-title":"Local and systemic adverse reactions to mRNA COVID-19 vaccines comparing two vaccine types and occurrence of previous COVID-19 infection","volume":"9","author":"Par\u00e9s-Badell","year":"2021","journal-title":"Vaccines."},{"key":"B5","first-page":"102","article-title":"Safety and adverse effects related to COVID-19 viral vector vaccines: a systematic review","volume":"23","author":"SeyedAlinaghi","year":"2024","journal-title":"Tanaffos."},{"key":"B6","doi-asserted-by":"publisher","first-page":"100546","DOI":"10.1016\/j.ctarc.2022.100546","article-title":"COVID-19 vaccine associated axillary lymphadenopathy - a systematic review","volume":"31","author":"Co","year":"2022","journal-title":"Cancer Treat Res Commun."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1001\/jama.2021.1967","article-title":"Reports of anaphylaxis after receipt of mRNA COVID-19 vaccines in the US-December 14, 2020-January 18, 2021","volume":"325","author":"Shimabukuro","year":"2021","journal-title":"JAMA."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5585","DOI":"10.1016\/j.vaccine.2022.08.007","article-title":"Thrombosis with thrombocytopenia after AZD1222 (ChAdOx1 nCov-19) vaccination: case characteristics and associations","volume":"40","author":"Laffan","year":"2022","journal-title":"Vaccine."},{"key":"B9","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.thromres.2022.09.017","article-title":"Vaccine-associated thrombocytopenia","volume":"220","author":"Gan","year":"2022","journal-title":"Thromb Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1001\/jamaneurol.2023.5208","article-title":"SARS-CoV-2 vaccination and neuroimmunological disease: a review","volume":"81","author":"Willison","year":"2024","journal-title":"JAMA Neurol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.nrleng.2022.09.007","article-title":"Neurological manifestations associated with COVID-19 vaccine","volume":"40","author":"Alonso Castillo","year":"2025","journal-title":"Neurologia (Engl Ed)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1100617","DOI":"10.3389\/fphar.2023.1100617","article-title":"Real-world evidence of autoimmune hepatitis following COVID-19 vaccination: a population-based pharmacovigilance analysis","volume":"14","author":"Chen","year":"2023","journal-title":"Front Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1056\/NEJMoa2110475","article-title":"Safety of the BNT162b2 mRNA covid-19 vaccine in a nationwide setting","volume":"385","author":"Barda","year":"2021","journal-title":"N Engl J Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"e11385","DOI":"10.1016\/j.heliyon.2022.e11385","article-title":"Myocardial infarction following COVID-19 vaccine administration; a systematic review","volume":"8","author":"Baqi","year":"2022","journal-title":"Heliyon."},{"key":"B15","doi-asserted-by":"publisher","first-page":"e134","DOI":"10.1017\/S0950268824001213","article-title":"The impact of COVID-19 status and vaccine type following the first dose on acute heart disease: a nationwide retrospective cohort study in south korea","volume":"152","author":"Yun","year":"2024","journal-title":"Epidemiol Infect."},{"key":"B16","doi-asserted-by":"publisher","first-page":"921760","DOI":"10.3389\/fphar.2022.921760","article-title":"Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26","volume":"13","author":"Yan","year":"2022","journal-title":"Front Pharmacol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e807","DOI":"10.1002\/iid3.807","article-title":"Adverse events following COVID-19 mRNA vaccines: a systematic review of cardiovascular complication, thrombosis, and thrombocytopenia","volume":"11","author":"Yasmin","year":"2023","journal-title":"Immun Inflammation Dis."},{"key":"B18","doi-asserted-by":"publisher","first-page":"e66549","DOI":"10.7759\/cureus.66549","article-title":"Cardiac arrhythmias and their management: an in-depth review of current practices and emerging therapies","volume":"16","author":"Nagpal","year":"2024","journal-title":"Cureus."},{"key":"B19","doi-asserted-by":"publisher","first-page":"100418","DOI":"10.1016\/j.jvacx.2023.100418","article-title":"Risk of cardiac arrhythmia and cardiac arrest after primary and booster COVID-19 vaccination in England: a self-controlled case series analysis","volume":"15","author":"Stowe","year":"2023","journal-title":"Vaccine X."},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2024.02.065","article-title":"Overview of US COVID-19 vaccine safety surveillance systems","author":"Gee","year":"2024","journal-title":"Vaccine"},{"key":"B21","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","article-title":"The REporting of a disproportionality analysis for DrUg safety signal detection using individual case safety reports in PharmacoVigilance (READUS-PV): explanation and elaboration","volume":"47","author":"Fusaroli","year":"2024","journal-title":"Drug Saf."},{"key":"B22","doi-asserted-by":"publisher","first-page":"17301","DOI":"10.1038\/s41598-025-02359-3","article-title":"A disproportionality analysis of adverse events associated with ertapenem using the FAERS database from 2004 to 2024","volume":"15","author":"Tang","year":"2025","journal-title":"Sci Rep."},{"key":"B23","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1038\/s41591-021-01630-0","article-title":"Risks of myocarditis, pericarditis, and cardiac arrhythmias associated with COVID-19 vaccination or SARS-CoV-2 infection","volume":"28","author":"Patone","year":"2022","journal-title":"Nat Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1093\/ehjqcco\/qcae111","article-title":"Impact of COVID-19 pandemic on the incidence and prevalence of postural orthostatic tachycardia syndrome","volume":"11","author":"Dulal","year":"2025","journal-title":"Eur Heart J Qual Care Clin Outcomes."},{"key":"B25","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1113\/EP090802","article-title":"Long COVID: Mechanisms, risk factors and recovery","volume":"108","author":"Astin","year":"2023","journal-title":"Exp Physiol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1292568","DOI":"10.3389\/fimmu.2023.1292568","article-title":"Rapid transient and longer-lasting innate cytokine changes associated with adaptive immunity after repeated SARS-CoV-2 BNT162b2 mRNA vaccinations","volume":"14","author":"Rosati","year":"2023","journal-title":"Front Immunol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"6703","DOI":"10.1038\/s41467-023-42559-x","article-title":"Activation of coagulation and proinflammatory pathways in thrombosis with thrombocytopenia syndrome and following COVID-19 vaccination","volume":"14","author":"Aid","year":"2023","journal-title":"Nat Commun."},{"key":"B28","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1016\/j.jacbts.2022.12.004","article-title":"Fir(e)ing the rhythm: Inflammatory cytokines and cardiac arrhythmias","volume":"8","author":"Lazzerini","year":"2023","journal-title":"JACC Basic Transl Sci."},{"key":"B29","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41577-022-00714-3","article-title":"Inflammatory cytokines and cardiac arrhythmias: the lesson from COVID-19","volume":"22","author":"Lazzerini","year":"2022","journal-title":"Nat Rev Immunol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1093\/europace\/euy067","article-title":"Sex differences in cardiac arrhythmia: a consensus document of the european heart rhythm association, endorsed by the heart rhythm society and asia pacific heart rhythm society","volume":"20","author":"Linde","year":"2018","journal-title":"Europace."},{"key":"B32","doi-asserted-by":"publisher","first-page":"4398","DOI":"10.1016\/j.vaccine.2015.07.035","article-title":"Safety monitoring in the vaccine adverse event reporting system (VAERS)","volume":"33","author":"Shimabukuro","year":"2015","journal-title":"Vaccine."},{"key":"B33","doi-asserted-by":"publisher","first-page":"7458","DOI":"10.1016\/j.vaccine.2020.09.072","article-title":"The reporting sensitivity of the vaccine adverse event reporting system (VAERS) for anaphylaxis and for guillain-barr\u00e9 syndrome","volume":"38","author":"Miller","year":"2020","journal-title":"Vaccine."},{"key":"B34","doi-asserted-by":"publisher","first-page":"168","DOI":"10.3390\/pharmaceutics5010168","article-title":"Vaccine safety surveillance systems: critical elements and lessons learned in the development of the US vaccine safety datalink's rapid cycle analysis capabilities","volume":"5","author":"Davis","year":"2013","journal-title":"Pharmaceutics."}],"container-title":["Frontiers in Public Health"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1762082\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:33:55Z","timestamp":1780896835000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpubh.2026.1762082\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,8]]},"references-count":34,"alternative-id":["10.3389\/fpubh.2026.1762082"],"URL":"https:\/\/doi.org\/10.3389\/fpubh.2026.1762082","relation":{},"ISSN":["2296-2565"],"issn-type":[{"value":"2296-2565","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,8]]},"article-number":"1762082"}}